Reversin 121
Modify Date: 2024-04-05 10:44:12
Reversin 121 structure
|
Common Name | Reversin 121 | ||
|---|---|---|---|---|
| CAS Number | 174630-04-7 | Molecular Weight | 641.75200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H47N3O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Reversin 121Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers[1][2]. |
| Name | 2-Methyl-2-propanyl (2S)-6-{[(benzyloxy)carbonyl]amino}-2-{[(2S)- 4-(benzyloxy)-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-4-oxo butanoyl]amino}hexanoate (non-preferred name) |
|---|
| Description | Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers[1][2]. |
|---|---|
| Related Catalog | |
| Target |
P-glycoprotein[1] |
| In Vitro | Reversin 121 (12 μg/mL) (with gemcitabine (HY-17026)) reduces the proportions of tumor cells positive for MDR proteins in Panc1 cell[1]. Reversin 121 (5 μM) reverses the resistance against paclitaxel in paclitaxel-resistant NCI-H460 cell[2]. Reversin 121 (10 μM, 48 h) inhibits T cell proliferation[3]. |
| In Vivo | Reversin 121 (2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day, i.p.) decreases tumor size and prevalence of metastases[1]. Animal Model: Orthotopic pancreatic carcinoma mouse model[1]. Dosage: 2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day Administration: Intraperitoneal injection (i.p.), 5 days a week Result: Decreased in MRP3-positive cells. |
| Molecular Formula | C34H47N3O9 |
|---|---|
| Molecular Weight | 641.75200 |
| Exact Mass | 641.33100 |
| PSA | 168.83000 |
| LogP | 6.18550 |